{"id":877439,"date":"2025-08-20T08:20:26","date_gmt":"2025-08-20T12:20:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\/"},"modified":"2025-08-20T08:20:26","modified_gmt":"2025-08-20T12:20:26","slug":"phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\/","title":{"rendered":"Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder\u2019s Ownership Following Administrative Change to 13D Filing"},"content":{"rendered":"<div class=\"mw_release\">\n<p>FLORHAM PARK, N.J., Aug.  20, 2025  (GLOBE NEWSWIRE) &#8212; Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August 20, will include administrative changes to its reporting approach but does not represent a reduction in the ownership position of any Frazier fund or person in Phathom.<\/p>\n<p>While the breakout of holdings between funds and persons may appear different than prior filings, and the treatment of warrants may reduce certain percentages in the updated filings, these differences are due solely to clarifying changes in Frazier\u2019s reporting approach and not to any sale of shares.\u00a0<\/p>\n<p>\n        <strong><br \/>\n          <u>About Phathom Pharmaceuticals, Inc.<\/u><br \/>\n        <\/strong>\u00a0<br \/>Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA<sup>\u00ae<\/sup>\u00a0(vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA<sup>\u00ae<\/sup>\u00a0TRIPLE PAK<sup>\u00ae<\/sup>\u00a0(vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA<sup>\u00ae<\/sup>\u00a0DUAL PAK<sup>\u00ae<\/sup>\u00a0(vonoprazan tablets, amoxicillin capsules) for the treatment\u00a0<em>of\u00a0H. pylori<\/em>\u00a0infection in adults. For more information about Phathom, visit the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BcJRBRfUs9jcBVf-aBywWX2etdX75MKGqLAjH4UJcoxRYM8FUlckgaHyQiVxRPW2-0IpqPDTbvF69f4wGuHLeobb5doyK7y2ydJ7uy5Gmmg=\" rel=\"nofollow\" target=\"_blank\">www.phathompharma.com<\/a> and follow on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9_vv-V7TL6yEzGH-KutUEZGXJsbjHeruvTIJKkLb7E11ocPaUiZB8Th4UHWuNJ4HbKM8sn-k3DLXxKhQbEFmEokqYNpzyj-yGs8NMtpkUsI=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w3MOe0IOKpfSzFkj-5imIzk_cfPsCXI9Etrr7UbpqBh9j4TpodxwSnGrV1veytVm2nvr3d1J4VROIP6D4o-BSg==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>MEDIA CONTACT<\/strong><br \/>\n        <br \/>Nick Benedetto<br \/>1-877-742-8466<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qqkffhlQa4jYlzEo3yjWTTb-icpJ06VdLU6azuRPVltPuM1R72dZDtXlyZJbqK_H1lJ8xMFqyzZVjVsf65gxmRvLBXVCUxgJLHGUZuvW6pQ=\" rel=\"nofollow\" target=\"_blank\"><u>media@phathompharma.com<\/u><\/a><\/p>\n<p>\n        <strong>INVESTOR CONTACT<\/strong><br \/>\n        <br \/>Eric Sciorilli<br \/>1-877-742-8466<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wF6hgc1DMB66_S11wPRGYajS5WjFSC2WVZbdMB64f2i2_NqLog_9YJSiJIaNpZRsmTrrWwrnbnY32_qnGX4qSgauafpGorVuw2WQon6kXlA=\" rel=\"nofollow\" target=\"_blank\"><u>ir@phathompharma.com<\/u><\/a><\/p>\n<p>\u00a9 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTI3NCM3MTAxODIwIzIxODk1NzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OGU2N2YxODctZjcwNi00YjgwLTg5OTQtYjM1OTg1NjMyMTNiLTEyMDExMjUtMjAyNS0wOC0yMC1lbg==\/tiny\/Phathom-Pharmaceuticals.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) &#8212; Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August 20, will include administrative changes to its reporting approach but does not represent a reduction in the ownership position of any Frazier fund or person in Phathom. While the breakout of holdings between funds and persons may appear different than prior filings, and the treatment of warrants may reduce certain percentages in the updated filings, these differences are due solely to clarifying changes in Frazier\u2019s reporting approach and not to any sale of shares.\u00a0 About Phathom Pharmaceuticals, Inc. \u00a0Phathom Pharmaceuticals is a biopharmaceutical company focused on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder\u2019s Ownership Following Administrative Change to 13D Filing&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-877439","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder\u2019s Ownership Following Administrative Change to 13D Filing - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder\u2019s Ownership Following Administrative Change to 13D Filing - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) &#8212; Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August 20, will include administrative changes to its reporting approach but does not represent a reduction in the ownership position of any Frazier fund or person in Phathom. While the breakout of holdings between funds and persons may appear different than prior filings, and the treatment of warrants may reduce certain percentages in the updated filings, these differences are due solely to clarifying changes in Frazier\u2019s reporting approach and not to any sale of shares.\u00a0 About Phathom Pharmaceuticals, Inc. \u00a0Phathom Pharmaceuticals is a biopharmaceutical company focused on &hellip; Continue reading &quot;Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder\u2019s Ownership Following Administrative Change to 13D Filing&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T12:20:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTI3NCM3MTAxODIwIzIxODk1NzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder\u2019s Ownership Following Administrative Change to 13D Filing\",\"datePublished\":\"2025-08-20T12:20:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\\\/\"},\"wordCount\":295,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNTI3NCM3MTAxODIwIzIxODk1NzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\\\/\",\"name\":\"Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder\u2019s Ownership Following Administrative Change to 13D Filing - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNTI3NCM3MTAxODIwIzIxODk1NzI=\",\"datePublished\":\"2025-08-20T12:20:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNTI3NCM3MTAxODIwIzIxODk1NzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNTI3NCM3MTAxODIwIzIxODk1NzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder\u2019s Ownership Following Administrative Change to 13D Filing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder\u2019s Ownership Following Administrative Change to 13D Filing - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\/","og_locale":"en_US","og_type":"article","og_title":"Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder\u2019s Ownership Following Administrative Change to 13D Filing - Market Newsdesk","og_description":"FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) &#8212; Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August 20, will include administrative changes to its reporting approach but does not represent a reduction in the ownership position of any Frazier fund or person in Phathom. While the breakout of holdings between funds and persons may appear different than prior filings, and the treatment of warrants may reduce certain percentages in the updated filings, these differences are due solely to clarifying changes in Frazier\u2019s reporting approach and not to any sale of shares.\u00a0 About Phathom Pharmaceuticals, Inc. \u00a0Phathom Pharmaceuticals is a biopharmaceutical company focused on &hellip; Continue reading \"Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder\u2019s Ownership Following Administrative Change to 13D Filing\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-20T12:20:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTI3NCM3MTAxODIwIzIxODk1NzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder\u2019s Ownership Following Administrative Change to 13D Filing","datePublished":"2025-08-20T12:20:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\/"},"wordCount":295,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTI3NCM3MTAxODIwIzIxODk1NzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\/","name":"Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder\u2019s Ownership Following Administrative Change to 13D Filing - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTI3NCM3MTAxODIwIzIxODk1NzI=","datePublished":"2025-08-20T12:20:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTI3NCM3MTAxODIwIzIxODk1NzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTI3NCM3MTAxODIwIzIxODk1NzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phathom-pharmaceuticals-clarifies-that-there-is-no-reduction-in-lead-shareholders-ownership-following-administrative-change-to-13d-filing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder\u2019s Ownership Following Administrative Change to 13D Filing"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/877439","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=877439"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/877439\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=877439"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=877439"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=877439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}